Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center

Breast Cancer Res Treat. 2022 Nov;196(2):371-377. doi: 10.1007/s10549-022-06689-y. Epub 2022 Sep 17.

Abstract

Purpose: To present an overview of the management of male patients with Ductal Carcinoma In Situ of the breast (male DCIS).

Methods: We retrospectively studied all male patients with a diagnosis of pure DCIS from January 1999 to December 2018: 20 patients were identified in our cancer referral center. We collected data regarding clinical presentation, age of onset, radiological features, receptor status of the neoplasm, histological type, and the follow-up of those patients.

Results: The median age was 62 years (range 21-80). All patients underwent surgery, in 15/20 (75%) cases a mastectomy was carried out. Two patients (10%) underwent endocrine treatment and 1/20 (5%) underwent radiotherapy. The receptor status for 15/20 patients was documented: 13/15 patients were ER+/Pr+. In 3 cases the Ki 67% was positive (i.e., > 20%). All cases were negative for Her2. The median follow-up time was 9.0 years (IQR 4.0-13.7). Only one patient had an ipsilateral recurrence with the finding of an infiltrating carcinoma in the same breast after 14 years. The 5-year disease-free survival was 92.9%.

Conclusion: Pure DCIS in men is an extremely rare disease: proper diagnosis and management allow an excellent prognosis.

Keywords: Breast; Disease-free survival; Male DCIS; Surgery.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms* / diagnostic imaging
  • Breast Neoplasms* / therapy
  • Breast Neoplasms, Male*
  • Carcinoma, Ductal, Breast* / pathology
  • Carcinoma, Intraductal, Noninfiltrating* / diagnostic imaging
  • Carcinoma, Intraductal, Noninfiltrating* / therapy
  • Humans
  • Ki-67 Antigen
  • Male
  • Mastectomy
  • Mastectomy, Segmental
  • Middle Aged
  • Neoplasm Recurrence, Local / pathology
  • Referral and Consultation
  • Retrospective Studies
  • Young Adult

Substances

  • Ki-67 Antigen